BIIB - Alzheimer's Is Becoming The Ultimate Battlefield In Biopharma Creating Unprecedented Value And Opportunity For Investors

• Recent advances in understanding how soluble amyloid oligomers drive Alzheimer’s disease and new biomarkers are supporting the development of effective treatments that will reach the market in the near future.
• These scientific developments also provide a new way for investors to evaluate opportunities in this space.
• A new diagnostic assay for oligomers, currently in progress, could revolutionize Alzheimer’s treatment by directly measuring the toxin in the brains of patients and guiding the treatment.
• It will also accelerate drug development by allowing for more efficient clinical trials.
• Alzheon’s APOLLOE4 Phase 3 study serves as one example of how to build a strong foundation of clinical and biomarker data to improve the efficiency and increase the value of Alzheimer’s trials.

For further details see: